Abstract | CONTEXT: OBJECTIVE: DESIGN: This was a descriptive case series of up to 3.5 yr duration. SETTING: The study was conducted at a university hospital. PATIENTS: INTERVENTION: MAIN OUTCOME MEASURES: Plasma IGF-I and growth velocity were measured. RESULTS: In all three children, pegvisomant rapidly decreased plasma IGF-I concentrations. Growth velocity declined to subnormal or normal values. Statural growth fell into lower growth percentiles and acromegalic features resolved. Pituitary tumor size did not change in two children but increased in one boy despite concomitant therapy with a somatostatin analog. CONCLUSIONS:
|
Authors | Naila Goldenberg, Michael S Racine, Pamela Thomas, Bernard Degnan, William Chandler, Ariel Barkan |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 93
Issue 8
Pg. 2953-6
(Aug 2008)
ISSN: 0021-972X [Print] United States |
PMID | 18492755
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Receptors, Somatotropin
- Human Growth Hormone
- Insulin-Like Growth Factor I
- pegvisomant
|
Topics |
- Adolescent
- Age Determination by Skeleton
- Child
- Female
- Gigantism
(blood, drug therapy, physiopathology)
- Growth
- Human Growth Hormone
(analogs & derivatives, therapeutic use)
- Humans
- Insulin-Like Growth Factor I
(analysis)
- Male
- Pituitary Neoplasms
(pathology)
- Receptors, Somatotropin
(antagonists & inhibitors)
|